InMed Pharmaceuticals (INM) H.C. Wainwright 27th Annual Global Investment Conference summary

Conference overview

• The event featured presentations on proprietary small molecule drug candidates targeting CB1/CB2 receptors, with a focus on Alzheimer's, dry AMD, and dermatology programs.

• The company operates a profitable subsidiary, BayMedica, supplying rare cannabinoids to the health and wellness industry, providing near-term revenue.

• The R&D pipeline includes INM-901 for Alzheimer's, INM-089 for dry AMD, and INM-755 for dermatology, each at different stages of development.

• Strategic partnerships and co-development opportunities are being pursued to accelerate clinical progress and maximize value.

• Financial discipline and a strong cash position support R&D through 2026, with ongoing efforts to enhance shareholder value.

Alzheimer's program (INM-901)

• INM-901 targets multiple mechanisms in Alzheimer's, including neuroinflammation, neuroprotection, and neurogenesis.

• Preclinical studies show oral bioavailability, blood-brain barrier penetration, and significant reductions in neuroinflammation and amyloid beta.

• Long-term mouse model studies demonstrated cognitive and behavioral improvements, as well as molecular validation of neurogenesis.

• Ongoing work includes expanded molecular analysis, dose-ranging, and preparation for GLP studies and IND filing.

• Active engagement with potential partners and investors aims to accelerate clinical development.

Ophthalmology and dermatology programs

• INM-089 for dry AMD has shown preclinical efficacy in preserving retinal function and is aligned with standard clinical delivery methods.

• Next steps for INM-089 include mechanistic studies, pre-IND meeting, and GLP studies, with business development efforts underway.

• INM-755 completed a phase II trial in EB, with two-thirds of patients experiencing meaningful itch reduction; partnerships are sought for chronic itch indications.